Skip to main content

Main menu

  • Home
  • Content
    • Current Issue
    • Ahead of Print
    • Past Issues
    • Supplements
    • Article Type
  • Specialty
    • Articles by Specialty
  • CME/MOC
    • Articles
    • Calendar
  • Info For
    • Manuscript Submission
    • Authors & Reviewers
    • Subscriptions
    • About CCJM
    • Contact Us
    • Media Kit
  • Conversations with Leaders
  • Conference Coverage
    • Kidney Week 2024
    • CHEST 2024
    • ACR Convergence 2023
    • Kidney Week 2023
    • ObesityWeek 2023
    • IDWeek 2023
    • CHEST 2023
    • MDS 2023
    • IAS 2023
    • ACP 2023
    • AAN 2023
    • ACC / WCC 2023
    • AAAAI Meeting 2023
    • ACR Convergence 2022
    • Kidney Week 2022
    • AIDS 2022
  • Other Publications
    • www.clevelandclinic.org

User menu

  • Register
  • Log in

Search

  • Advanced search
Cleveland Clinic Journal of Medicine
  • Other Publications
    • www.clevelandclinic.org
  • Register
  • Log in
Cleveland Clinic Journal of Medicine

Advanced Search

  • Home
  • Content
    • Current Issue
    • Ahead of Print
    • Past Issues
    • Supplements
    • Article Type
  • Specialty
    • Articles by Specialty
  • CME/MOC
    • Articles
    • Calendar
  • Info For
    • Manuscript Submission
    • Authors & Reviewers
    • Subscriptions
    • About CCJM
    • Contact Us
    • Media Kit
  • Conversations with Leaders
  • Conference Coverage
    • Kidney Week 2024
    • CHEST 2024
    • ACR Convergence 2023
    • Kidney Week 2023
    • ObesityWeek 2023
    • IDWeek 2023
    • CHEST 2023
    • MDS 2023
    • IAS 2023
    • ACP 2023
    • AAN 2023
    • ACC / WCC 2023
    • AAAAI Meeting 2023
    • ACR Convergence 2022
    • Kidney Week 2022
    • AIDS 2022
COVID-19 Curbside Consults

Coagulopathy in COVID-19

Simon R. Mucha, MD, Siddharth Dugar, MD, Keith McCrae, MD, Douglas E. Joseph, DO, John Bartholomew, MD, Gretchen Sacha, PharmD, RPh, BCCCP and Michael Militello, PharmD, RPh, BCPS
Cleveland Clinic Journal of Medicine May 2020, DOI: https://doi.org/10.3949/ccjm.87a.ccc024
Simon R. Mucha
Critical Care Medicine, Respiratory Institute, Cleveland Clinic
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Siddharth Dugar
Pulmonary Medicine, Cleveland Clinic
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Keith McCrae
Hematology and Medical Oncology, Cleveland Clinic
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Douglas E. Joseph
Cardiovascular Medicine, Cleveland Clinic
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
John Bartholomew
Cardiovascular Medicine, Cleveland Clinic
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Gretchen Sacha
Inpatient Pharmacy, Cleveland Clinic
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Michael Militello
Inpatient Pharmacy, Cleveland Clinic
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
View current version of this article
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Article Figures & Data

Figures

  • Tables
  • Figure 1
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 1

    A short axis view of the femoral vein (FV), the femoral artery (FA) at the site of the saphenous vein inflow (SV). Amorphous echogenicity in the femoral vein, greater than that of the adjacent femoral artery is suggestive of “slow venous flow.” The vein is fully compressible ruling out deep vein thrombosis at the site.

  • Figure 2
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 2

Tables

  • Figures
    • View popup
    TABLE 1
    Category 1
    D-dimer < 3,000 ng/mL
    FEU
    Standard prophylaxis
    Category 2
    D-dimer > 3,000 ng/mL
    FEU
    High-intensity prophylaxis
    Category 3
    Confirmed VTE
    Standard doseEnoxaparin 40 mg SC q24hEnoxaparin 40 mg SC q12hIV Heparin DVT/PE nomogram or Enoxaparin 1 mg/kgSC q12h
    Renal failure
    ‡AKI definition: Doubling of creatinine in 48h or anuria
    CrCI > 10-30mL/min:
    Enoxaparin 30 mg SC q24h
    CrCI < 30 mL/min or AKI:
    Enoxaparin 40 mg SC q24h
    IV heparin DVT/VTE nomogram
    CrCI < 10 mL/min or
    AKI‡:
    UFH 5,000 USCq12h
    CrCI < 10 mL/min or AKI‡:
    UFH 7500 U SC ql2h
    CRRT:
    500 U/h through circuit Circuit clotting:
    IV ACS nomogram
    CRRT:
    500 U/h through circuit Circuit clotting:
    IV ACS nomogram
    Obesity
    Standard> 100 kg:
    Enoxaparin 40 mg SC q12h
    > 120 kg:
    Enoxaparin 60 mg SC q12h
    > 100 kg:
    Enoxaparin 60 mg SC q12h
    > 120 kg:
    Enoxaparin 80 mg SC q12h
    IV Heparin DVT/PE nomogram or Enoxaparin 1 mg/kgSC q12h - up to 150 mg
    Above 150 kg use UFH
    Renal failure
    30mL/min or AKI‡
    ‡AKI definition: Doubling of creatinine in 48h or anuria
    ≤ 120 kg: 7,500 U q12h
    > 120kg: 10,000U q12h
    ≤ 120 kg: 7,500 U q8h
    > 120kg: 10,000U q8h
    IV heparin DVT/PE nomogram
    CRRT:
    500 U/h through circuit Circuit clotting:
    IV Heparin ACS‡ nomogram
    CRRT:
    500 U/h through circuit Circuit clotting:
    IV Heparin ACS‡ nomogram
    IV Heparin ACS nomogram: initial dose 60-U/kg bolus, 12 U/kg/h
     - Target =aPTT49 – 67 seconds
     - Target heparin anti-Xa. 0.2 - 0.5 until/ml
    • ACS = acute coronary syndrome; AKI = acute kidney injury; aPTT = activated partial thromboplastin time; CrCl = creatinine clearance; CRRT = continuous renal replacement therapy; DVT = deep vein thrombosis; FEU = fibrinogen equivalent units; IV = intravenous; PE = pulmonary embolism; SC = subcutaneously; UFH = unfractionated heparin

Next
Back to top

In this issue

Cleveland Clinic Journal of Medicine: 92 (6)
Cleveland Clinic Journal of Medicine
Vol. 92, Issue 6
1 Jun 2025
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
  • Complete Issue (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Cleveland Clinic Journal of Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Coagulopathy in COVID-19
(Your Name) has sent you a message from Cleveland Clinic Journal of Medicine
(Your Name) thought you would like to see the Cleveland Clinic Journal of Medicine web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Coagulopathy in COVID-19
Simon R. Mucha, Siddharth Dugar, Keith McCrae, Douglas E. Joseph, John Bartholomew, Gretchen Sacha, Michael Militello
Cleveland Clinic Journal of Medicine May 2020, DOI: 10.3949/ccjm.87a.ccc024

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Coagulopathy in COVID-19
Simon R. Mucha, Siddharth Dugar, Keith McCrae, Douglas E. Joseph, John Bartholomew, Gretchen Sacha, Michael Militello
Cleveland Clinic Journal of Medicine May 2020, DOI: 10.3949/ccjm.87a.ccc024
Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Linkedin Share Button

Jump to section

  • Article
    • ABSTRACT
    • CLINICAL MANIFESTATIONS
    • LABORATORY FINDINGS
    • HISTOPATHOLOGY
    • PATHOPHYSIOLOGY
    • MANAGEMENT
    • LABORATORY TESTING
    • IMAGING
    • TREATMENT
    • CONTINUOUS RENAL REPLACEMENT THERAPY
    • DURATION OF ANTICOAGULATION
    • SUMMARY
    • Footnotes
    • REFERENCES
  • Figures & Data
  • Info & Metrics
  • PDF

Related Articles

  • PubMed
  • Google Scholar

Cited By...

  • Retinal microvascular abnormalities in patients after COVID-19 depending on disease severity
  • In Reply: COVID-19 coagulopathy
  • COVID-19 coagulopathy
  • The hospitalized patient with COVID-19 on the medical ward: Cleveland Clinic approach to management
  • Google Scholar

More in this TOC Section

  • Update to COVID-19 serologic testing : FAQs and caveats
  • Update to post-acute sequelae of SARS-CoV-2 infection: Caring for the 'long-haulers'
  • COVID-19 in older adults
Show more COVID-19 Curbside Consults

Similar Articles

Subjects

  • Critical Care
  • Drug Therapy
  • Hematology
  • Hospital Medicine
  • Imaging
  • Infectious Diseases
  • Pulmonology
  • Vascular Medicine

Navigate

  • Current Issue
  • Past Issues
  • Supplements
  • Article Type
  • Specialty
  • CME/MOC Articles
  • CME/MOC Calendar
  • Media Kit

Authors & Reviewers

  • Manuscript Submission
  • Authors & Reviewers
  • Subscriptions
  • About CCJM
  • Contact Us
  • Cleveland Clinic Center for Continuing Education
  • Consult QD

Share your suggestions!

Copyright © 2025 The Cleveland Clinic Foundation. All rights reserved. The information provided is for educational purposes only. Use of this website is subject to the website terms of use and privacy policy. 

Powered by HighWire